Delivery Order SPE2DB20D1100-SPE2DB25FE0JZ
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $4,131.74 to AmerisourceBergen Drug Corp for the supply of Prograf 1 mg capsules (100-count units). This firm fixed-price delivery order, issued on August 4, 2025, with an ultimate completion date of August 5, 2025, represents a competitive award with no set-aside designation. The pharmaceutical product will be delivered to the contractor's facility in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate...
- The Defense Logistics Agency awarded a delivery order valued at $36,127.45 to AmerisourceBergen Drug Corp for the supply of Prograf 1 mg capsules (100-count units) on July 18, 2025, with an ultimate completion date of July 21, 2025. This non-set-aside, firm fixed-price contract was competitively awarded and represents a routine pharmaceutical procurement supporting federal medical supply needs. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a critical...
- The Defense Logistics Agency awarded a delivery order valued at $3,607.93 to AmerisourceBergen Drug Corp for the supply of Prograf 1 mg capsules (100-count units). This firm fixed-price delivery order, issued on July 31, 2025, with an ultimate completion date of August 1, 2025, represents a non-competitive set-aside procurement. The product will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency awarded a $1,738.12 delivery order to AmerisourceBergen Drug Corp on June 25, 2025, for the supply of Prograf 1 mg capsules (100-count units). This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and running through December 2026. The pharmaceutical product will be delivered to AmerisourceBergen's corporate...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $7,657.94 by the Defense Logistics Agency (DLA) on July 31, 2025, for the supply of Prograf 1 mg capsules in quantities of 100 units. This contract is a firm fixed-price delivery order with an ultimate completion date of August 1, 2025, and was competitively awarded without set-aside designation. The award represents a child contract under a larger indefinite delivery contract...
- The Defense Logistics Agency awarded a $1,393.41 delivery order to AmerisourceBergen Drug Corp for Prograf 5 mg/mL ampules, with an ultimate completion date of September 15, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a child order under AmerisourceBergen's larger indefinite delivery contract vehicle with DLA Troop Support Medical. The work will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. This...
- This is a firm fixed price delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, a leading global pharmaceutical sourcing and distribution services company. The $3,107.15 contract is for the delivery of Prograf 1 mg capsules, a specialty medication, to support military treatment programs and facilities. Amerisourcebergen Drug Corp holds an indefinite delivery contract (IDC) with DLA, valued at up to...
- This federal contract award, valued at $1,230.00, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award is a delivery order contract for the supply of Prograf 1 mg capsules, a medication used for transplant patients. The contract has an ultimate completion date of September 24, 2024 and is a firm fixed-price agreement. It is not designated as a set-aside contract, indicating open...
- This is a delivery order issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor, to provide 4,565,736 units of the prescription medication Prograf 1 mg capsules. The order is a firm fixed-price contract valued at $15,062.59 and will be delivered by September 10, 2024. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999 through December 2025, for...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation for Prograf 1 mg capsules. The contract has a ceiling value of $1,454.98 and is a firm fixed price contract type. The place of performance is Conshohocken, Pennsylvania. This delivery order is associated with a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999 through December 2025, for a comprehensive range of medical commodities...
- SPE2DB20D1100Indefinite Delivery Contract
- SPE2DB20D1100-SPE2DB25FE0JZDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $41,735.37 to AmerisourceBergen Drug Corp for the supply of Prograf 5 mg capsules (100 count units) under a firm fixed price contract. The award was made on September 17, 2025, with an ultimate completion date of September 18, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. This non-set-aside award represents a competitively awarded transaction for a critical pharmaceutical product used in immunosuppressive therapy, particularly for transplant recipients within the military and federal healthcare systems. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. As a major pharmaceutical distributor and premier federal medical supply vendor, AmerisourceBergen Drug Corp serves as a critical supplier to the Defense Health Agency and other federal healthcare systems. The company's portfolio demonstrates extensive capability across multiple therapeutic domains, including specialty medications, brand-name and generic drugs, and medical supplies, positioning it as a key provider within the DLA's pharmaceutical prime vendor program supporting military healthcare operations globally.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $41.7k | 9/17/25 |